We have discovered two metal ion binding compounds, pyrithione (PT) and hinokitiol (HK), that efficiently inhibit human rhinovirus, coxsackievirus, and mengovirus multiplication. Early stages of virus infection are unaffected by these compounds. However, the cleavage of the cellular eukaryotic translation initiation factor eIF4GI by the rhinoviral 2A protease was abolished in the presence of PT and HK. We further show that these compounds inhibit picornavirus replication by interfering with proper processing of the viral polyprotein.
Available evidence suggests that a combination of Zinc + Hinokitiol are synergistic in inhibiting growth of viruses including SARS-COV. Dr ZinX Oral Spray is a novel patented oral formulation (Patent number: 2020900820) consisting of Zinc and Hinokitiol. Dr ZinX has the potential to reduce the viral load in oral mucosa, reducing chances of human-human transmission and severity of COVID-19.